B
Brian I. Rini
Researcher at Vanderbilt University Medical Center
Publications - 652
Citations - 49231
Brian I. Rini is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 89, co-authored 608 publications receiving 38953 citations. Previous affiliations of Brian I. Rini include University of California, San Francisco & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).
Andrew B. Nixon,Susan Halabi,Ivo D. Shterev,Mark D. Starr,John C. Brady,Janice P. Dutcher,Judith O. Hopkins,Herbert Hurwitz,Eric J. Small,Brian I. Rini,Phillip G. Febbo,Daniel J. George +11 more
TL;DR: CALGB 90206 was a phase III trial of 732 pts with RCC comparing B+I versus I alone demonstrating no difference in OS, and no validated predictive biomarkers for B in...
Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Andrew Schmidt,Matthew D Tucker,Ziad Bakouny,Chris Labaki,Chih-Yuan Hsu,Yu Shyr,Andrew J. Armstrong,Tomasz M. Beer,Ragneel R Bijjula,Mehmet Asim Bilen,Cindy F Connell,Scott J. Dawsey,Bryan A. Faller,Xin Gao,Benjamin A. Gartrell,David Gill,Shuchi Gulati,Susan Halabi,Clara Hwang,Monika Joshi,Ali Raza Khaki,Ali Raza Khaki,Harry Menon,Michael J. Morris,Matthew Puc,Karen B Russell,Neil J. Shah,Nima Sharifi,Justin Shaya,Michael T. Schweizer,John A. Steinharter,Elizabeth Marie Wulff-Burchfield,Wenxin Xu,Jay Zhu,Sanjay Mishra,Petros Grivas,Brian I. Rini,Jeremy L. Warner,Tian Zhang,Toni K. Choueiri,Shilpa Gupta,Rana R. McKay +41 more
TL;DR: In this article, the authors examined whether ADT is associated with a decreased rate of 30-day mortality from SARS-CoV-2 infection among patients with prostate cancer.
Journal ArticleDOI
711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
Laurence Albiges,Nizar M. Tannir,Mauricio Burotto,David F. McDermott,Elizabeth R. Plimack,Philippe Barthélémy,C. Porta,Thomas Powles,Frede Donskov,Saby George,Christian K. Kollmannsberger,Howard Gurney,M.-O. Grimm,Yoshihiko Tomita,D. Castellano Gauna,Brian I. Rini,Toni K. Choueiri,Shruti Shally Saggi,M.B. McHenry,Robert J. Motzer +19 more
Journal ArticleDOI
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Meta H M Diekstra,Jesse J. Swen,Epie Boven,Daniel Castellano,Hans Gelderblom,Ron H.J. Mathijssen,Cristina Rodríguez-Antona,Jesús García-Donas,Brian I. Rini,Henk-Jan Guchelaar +9 more
TL;DR: A total of 22 SNPs and 6 haplotypes in 10 candidate genes related to pharmacokinetics and pharmacodynamics of sunitinib were tested for associations with toxicity, dose reductions, progression-free survival (PFS), overall survival (OS) and best objective response.
Journal ArticleDOI
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes.
Christian Rothermundt,Alexandra S. Bailey,Linda Cerbone,Tim Eisen,Bernard Escudier,Silke Gillessen,Viktor Grünwald,James Larkin,David F. McDermott,Jan Oldenburg,Camillo Porta,Brian I. Rini,Manuela Schmidinger,Cora N. Sternberg,Paul Martin Putora,Paul Martin Putora +15 more
TL;DR: The results illustrate the heterogeneity of the decision criteria and treatment strategies for mccRCC and how available data are interpreted and implemented differently among experts.